William Blair Weighs in on Incyte Co.’s Q1 2025 Earnings (NASDAQ:INCY)

Incyte Co. (NASDAQ:INCY) – Analysts at William Blair raised their Q1 2025 earnings per share (EPS) estimates for shares of Incyte in a research report issued on Tuesday, April 23rd. William Blair analyst M. Phipps now forecasts that the biopharmaceutical company will earn $0.90 per share for the quarter, up from their prior estimate of $0.71. William Blair has a “Outperform” rating on the stock. The consensus estimate for Incyte’s current full-year earnings is $3.85 per share.

A number of other research firms have also weighed in on INCY. Oppenheimer cut their price objective on shares of Incyte from $92.00 to $84.00 and set an “outperform” rating for the company in a research report on Wednesday. Jefferies Financial Group initiated coverage on Incyte in a research note on Friday, February 23rd. They set a “buy” rating and a $81.00 price target on the stock. Royal Bank of Canada restated a “sector perform” rating and set a $65.00 price objective on shares of Incyte in a report on Monday, March 25th. JMP Securities lowered Incyte from an “outperform” rating to a “market perform” rating in a research note on Wednesday, February 14th. Finally, Cantor Fitzgerald began coverage on Incyte in a research report on Tuesday. They set a “neutral” rating on the stock. Nine analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $75.50.

Incyte Price Performance

NASDAQ:INCY opened at $51.18 on Thursday. Incyte has a 12-month low of $50.27 and a 12-month high of $75.74. The firm has a market cap of $11.49 billion, a price-to-earnings ratio of 19.31, a price-to-earnings-growth ratio of 1.19 and a beta of 0.65. The company’s 50-day moving average is $56.90 and its two-hundred day moving average is $57.73. The company has a current ratio of 3.55, a quick ratio of 3.36 and a debt-to-equity ratio of 0.01.

Incyte (NASDAQ:INCY) last posted its quarterly earnings data on Tuesday, February 13th. The biopharmaceutical company reported $1.06 EPS for the quarter, missing analysts’ consensus estimates of $1.15 by ($0.09). The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1 billion. Incyte had a net margin of 16.17% and a return on equity of 12.56%. The firm’s revenue was up 9.3% on a year-over-year basis. During the same period in the previous year, the business earned $0.44 EPS.

Institutional Trading of Incyte

A number of institutional investors and hedge funds have recently bought and sold shares of INCY. New York State Teachers Retirement System increased its position in shares of Incyte by 1.9% in the first quarter. New York State Teachers Retirement System now owns 203,649 shares of the biopharmaceutical company’s stock worth $11,602,000 after acquiring an additional 3,739 shares in the last quarter. Capital Investment Advisory Services LLC purchased a new position in shares of Incyte during the 1st quarter valued at approximately $318,000. Fjarde AP Fonden Fourth Swedish National Pension Fund increased its stake in shares of Incyte by 24.6% in the first quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 115,364 shares of the biopharmaceutical company’s stock worth $6,572,000 after buying an additional 22,800 shares during the last quarter. Wealth Advisory Solutions LLC acquired a new stake in Incyte in the first quarter valued at $346,000. Finally, Legacy Trust boosted its stake in Incyte by 26.7% during the 1st quarter. Legacy Trust now owns 36,899 shares of the biopharmaceutical company’s stock valued at $2,102,000 after acquiring an additional 7,783 shares during the last quarter. Institutional investors and hedge funds own 96.97% of the company’s stock.

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.